REL

Across TCGA pan-cancer cohorts, REL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated REL data layer compared with 27 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher REL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated REL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and CHOL are the cancer types where REL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.238	0.686	.031	9	view →
UCEC	DFS	Median	All	0.970	0.828	.019	8	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

REL–HNSC (OS)

Open the HNSC breakdown →